CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 3.77: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
1.09BUSDvs all stocks (USD)
Revenue (TTM)
322.02MUSDvs all stocks (USD)
Profit Margin
-31.82%vs Medical Devices peers
Beta
0.8690xvs all stocks
52-Week Change
-66.31%vs all stocks
Market Capitalization
1.09BUSDvs all stocks (USD)
Enterprise Value
926.34MUSDvs all stocks (USD)
Forward P/E
-21.57xvs Medical Devices peers
Price to Sales (TTM)
3.40xvs Medical Devices peers
Price to Book (MRQ)
3.15xvs Medical Devices peers
Enterprise to Revenue
2.88xvs Medical Devices peers
Enterprise to EBITDA
-9.05xvs Medical Devices peers
Gross Margin
64.89%vs Medical Devices peers
Profit Margin
-31.82%vs Medical Devices peers
Operating Margin
-39.22%vs Medical Devices peers
Return on Assets (TTM)
-13.54%vs Medical Devices peers
Return on Equity (TTM)
-27.82%vs Medical Devices peers
Revenue (TTM)
322.02MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.76USDUpdated Jul 19, 2026Quarterly Revenue Growth
20.20%vs Medical Devices peers
Gross Profit (TTM)
206.01MUSDvs all stocks (USD)
EBITDA (TTM)
-102.38MUSDvs all stocks (USD)
Net Income (TTM)
-102.47MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
20.20%vs Medical Devices peers
Operating Cash Flow (TTM)
-70.13MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-43.18MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Medical Devices peers
Revenue
308.05MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
111.83MUSDFY2025 · Dec 31, 2025Gross Profit
196.23MUSDFY2025 · Dec 31, 2025Operating Income
-103.86MUSDvs all stocks (USD)
Pre-tax Income
-95.38MUSDFY2025 · Dec 31, 2025Income Tax Expense
190.00KUSDFY2025 · Dec 31, 2025Net Income
-95.57MUSDFY2025 · Dec 31, 2025EBIT
-91.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-85.41MUSDFY2025 · Dec 31, 2025Research & Development
71.28MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
228.81MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.22MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.59MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.72USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.72USDFY2025 · Dec 31, 2025Basic Shares Outstanding
55.54MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
55.54MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-95.57MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-59.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
289.54MUSDFY2025 · Dec 31, 2025Interest Paid
3.46MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-95.57MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.39MUSDFY2025 · Dec 31, 2025Stock-based Compensation
47.60MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-508.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-898.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.65MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.22MUSDFY2025 · Dec 31, 2025Capital Expenditures
-9.36MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-9.36MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
56.90MSharesUpdated Jul 19, 2026Float Shares
55.51MSharesUpdated Jul 19, 2026Shares Short
7.65MSharesUpdated Jul 19, 2026Short Ratio
4.51daysvs all stocks
Short % of Shares Outstanding
13.84%vs all stocks
% Held by Insiders
3.17%vs all stocks
% Held by Institutions
101.93%vs all stocks
Total Cash (MRQ)
245.64MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.32USDUpdated Jul 19, 2026Total Debt (MRQ)
78.00MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2243xvs Medical Devices peers
Current Ratio (MRQ)
6.73xvs Medical Devices peers
Book Value per Share (MRQ)
6.11USDUpdated Jul 19, 2026Total Assets
508.08MUSDvs all stocks (USD)
Total Current Assets
450.38MUSDFY2025 · Dec 31, 2025Total Liabilities
142.21MUSDFY2025 · Dec 31, 2025Total Non-current Assets
57.70MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
76.42MUSDFY2025 · Dec 31, 2025Total Current Liabilities
65.80MUSDFY2025 · Dec 31, 2025Cash
11.42MUSDFY2025 · Dec 31, 2025Cash Equivalents
275.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
286.50MUSDFY2025 · Dec 31, 2025Accounts Receivable
83.53MUSDFY2025 · Dec 31, 2025Inventory
70.69MUSDFY2025 · Dec 31, 2025Accounts Payable
17.29MUSDFY2025 · Dec 31, 2025Short-term Debt
2.21MUSDFY2025 · Dec 31, 2025Deferred Revenue
13.05MUSDFY2025 · Dec 31, 2025Other Current Liabilities
7.38MUSDFY2025 · Dec 31, 2025Long-term Debt
76.27MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
147.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-641.56MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
365.87MUSDvs all stocks (USD)
52-Week Low
17.96USDUpdated Jul 19, 202652-Week High
60.57USDUpdated Jul 19, 202652-Week Change
-66.31%vs all stocks
Beta
0.8690xvs all stocks
50-Day MA
24.29USDUpdated Jul 19, 2026200-Day MA
28.37USDUpdated Jul 19, 2026Avg 10-Day Volume
1.67MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.74MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.83USDUpdated Jul 19, 2026Other Income / Expense
-156.00KUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.20Receivables vs revenue divergence: 14.01
High gross margins eroded by operating costsNotable
Gross Margin: 0.65Profit Margin: -0.32
Financial Health
Altman Z-Score 3.77: safe zoneNotable
Altman Z-Score: 3.77
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Orum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cullinan Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sealsq Corp
4 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Delcath Systems Inc.
4 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
BTQ Technologies Corp.
4 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC